Live feed07:00:00·3dPRReleasevia QuantisnowU.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsByQuantisnow·Wall Street's wire, on your screen.CGEM· Cullinan Therapeutics Inc.Health Care
